Ontology highlight
ABSTRACT: Background
The effectiveness of nirmatrelvir-ritonavir has mainly been shown in non-hospitalized patients with mild-to-moderate coronavirus disease 2019 (COVID-19). The real-world effectiveness of nirmatrelvir-ritonavir urgently needs to be determined using representative in-hospital patients with COVID-19 during the Omicron wave of the pandemic.Methods
We performed a multicentre, retrospective study in five Chinese PLA General Hospital medical centers in Beijing, China. Patients hospitalized with COVID-19 from 10 December 2022 to 20 February 2023 were eligible for inclusion. A 1:1 propensity score matching was performed between the nirmatrelvir-ritonavir group and the control group.Results
1010 recipients of nirmatrelvir-ritonavir and 1010 matched controls were fin
SUBMITTER: Han X
PROVIDER: S-EPMC10868413 | biostudies-literature | 2024 Dec
REPOSITORIES: biostudies-literature